← All trials
NCT07023315
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2025
- Primary completion
- Jul 31, 2029
- Completion date
- Jul 31, 2031
- First posted
- Jun 16, 2025
- Last posted
- Jun 16, 2025
- Enrollment
- 760
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Akeso Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.